

# Dimitrios Daoussis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1450183/publications.pdf>

Version: 2024-02-01

79  
papers

2,263  
citations

279798

23  
h-index

233421

45  
g-index

80  
all docs

80  
docs citations

80  
times ranked

2414  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of osteoporosis and vertebral compression fractures on mortality and association with pulmonary function in COPD: A meta-analysis. <i>Joint Bone Spine</i> , 2022, 89, 105249.	1.6	9
2	ACTH vs steroids for the treatment of acute gout in hospitalized patients: a randomized, open label, comparative study. <i>Rheumatology International</i> , 2022, 42, 949-958.	3.0	2
3	TIPIC syndrome. <i>Joint Bone Spine</i> , 2022, 89, 105396.	1.6	0
4	DKK-1 Is Underexpressed in Mesenchymal Stem Cells from Patients with Ankylosing Spondylitis and Further Downregulated by IL-17. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6660.	4.1	11
5	Immune checkpoint inhibitor-induced musculoskeletal manifestations. <i>Rheumatology International</i> , 2021, 41, 33-42.	3.0	32
6	Rice bodies in MRI. <i>Joint Bone Spine</i> , 2021, 88, 105079.	1.6	1
7	A Case Report of Favourable Response of Polymyositis to Methotrexate Monotherapy. <i>Mediterranean Journal of Rheumatology</i> , 2021, 31, 86.	0.8	1
8	B cells in systemic sclerosis: from pathophysiology to treatment. <i>Clinical Rheumatology</i> , 2021, 40, 2621-2631.	2.2	15
9	Anti-PD-1 associated retroperitoneal fibrosis. <i>Rheumatology</i> , 2021, 60, e329-e330.	1.9	4
10	Renal dysfunction in systemic sclerosis beyond scleroderma renal crisis. <i>Rheumatology International</i> , 2021, 41, 1203-1208.	3.0	8
11	Grains de riz Ã lâ€™IRM. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 244.	0.0	0
12	Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed. <i>Rheumatology International</i> , 2021, 41, 1839-1843.	3.0	13
13	Foreign Body Dactylitis. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 158.	0.8	0
14	Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 218.	0.8	8
15	Serotonin and Systemic sclerosis. An emerging player in pathogenesis. <i>Joint Bone Spine</i> , 2021, 89, 105309.	1.6	3
16	First report of <i>Mycobacterium celatum</i> â€“induced arthritis. <i>Rheumatology</i> , 2020, 59, 1772-1773.	1.9	1
17	A study of antigen-specific anti-cytomegalovirus antibody reactivity in patients with systemic sclerosis and concomitant anti-Ro52 antibodies. <i>Rheumatology International</i> , 2020, 40, 1689-1699.	3.0	5
18	Adrenocorticotrophic hormone: an effective â€œnaturalâ€•biologic therapy for acute gout?. <i>Rheumatology International</i> , 2020, 40, 1941-1947.	3.0	7

#	ARTICLE	IF	CITATIONS
19	Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3389.	4.1	19
20	Neck pain, red eyes and hearing loss. <i>Rheumatology</i> , 2020, 59, 4002-4002.	1.9	0
21	An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding. <i>Rheumatology</i> , 2020, 59, 1041-1050.	1.9	25
22	Antigen-specific humoral responses against <i>Helicobacter pylori</i> in patients with systemic sclerosis. <i>Immunologic Research</i> , 2020, 68, 39-47.	2.9	6
23	Primary Sjögren's Syndrome and Cardiovascular Disease. <i>Current Vascular Pharmacology</i> , 2020, 18, 447-454.	1.7	28
24	Cardiovascular Disease in the Systemic Vasculitides. <i>Current Vascular Pharmacology</i> , 2020, 18, 463-472.	1.7	6
25	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 239.	0.8	2
26	A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic sclerosis. <i>Clinical Immunology</i> , 2019, 207, 87-96.	3.2	20
27	Comorbidity burden in systemic sclerosis: beyond disease-specific complications. <i>Rheumatology International</i> , 2019, 39, 1507-1517.	3.0	19
28	Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. <i>World Journal of Gastroenterology</i> , 2019, 25, 2162-2176.	3.3	122
29	Targeting very early systemic sclerosis: a case-based review. <i>Rheumatology International</i> , 2019, 39, 1961-1970.	3.0	15
30	B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis. <i>Rheumatology International</i> , 2019, 39, 1889-1898.	3.0	12
31	Painless, eosinophilic infiltration of temporal arteries. <i>Rheumatology</i> , 2019, 58, 2065-2067.	1.9	6
32	Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?. <i>Current Rheumatology Reports</i> , 2019, 21, 15.	4.7	26
33	AB0678 ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .		0
34	Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1133-1141.	3.4	32
35	Biologics in SAPHO syndrome: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 618-625.	3.4	74
36	Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 33-37.	0.8	14

#	ARTICLE	IF	CITATIONS
37	DISH vs Spondyloarthritides. Mediterranean Journal of Rheumatology, 2019, 31, 81.	0.8	5
38	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. Israel Medical Association Journal, 2019, 21, 292-297.	0.1	0
39	Intestinal Involvement in Systemic Sclerosis: A Clinical Review. Digestive Diseases and Sciences, 2018, 63, 834-844.	2.3	44
40	Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis. Frontiers in Immunology, 2018, 9, 2835.	4.8	12
41	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Research and Therapy, 2018, 20, 267.	3.5	24
42	Calcified lymph nodes and systemic sclerosis. Mediterranean Journal of Rheumatology, 2018, 29, 97-98.	0.8	2
43	ACTH vs betamethasone for the treatment of acute gout in hospitalized patients: A randomized, open label, comparative study. Mediterranean Journal of Rheumatology, 2018, 29, 178-181.	0.8	2
44	Dickkopf-1 is downregulated early and universally in the skin of patients with systemic sclerosis despite normal circulating levels. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 45-49.	0.8	3
45	The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis. Seminars in Arthritis and Rheumatism, 2017, 47, 409-417.	3.4	41
46	Immune checkpoint inhibitor-induced myo-fasciitis. Rheumatology, 2017, 56, 2161-2161.	1.9	18
47	A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Seminars in Arthritis and Rheumatism, 2017, 46, 625-631.	3.4	169
48	The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma?. Seminars in Arthritis and Rheumatism, 2017, 46, 430-438.	3.4	16
49	The Infectious Basis of ACPA-Positive Rheumatoid Arthritis. Frontiers in Microbiology, 2017, 8, 1853.	3.5	54
50	Is there a link between IL-23/IL-17 and developmental pathways such as the Wnt and Hedgehog pathway?. Mediterranean Journal of Rheumatology, 2017, 28, 59-61.	0.8	1
51	Dkk1: A key molecule in joint remodelling and fibrosis. Mediterranean Journal of Rheumatology, 2017, 28, 174-182.	0.8	13
52	Gout and foot drop. Joint Bone Spine, 2016, 83, 229.	1.6	1
53	Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study. BMC Musculoskeletal Disorders, 2016, 17, 213.	1.9	12
54	Periaortitis, hairy kidneys and bone lesions. Rheumatology, 2016, 55, 2118-2118.	1.9	6

#	ARTICLE	IF	CITATIONS
55	B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. <i>Arthritis Research and Therapy</i> , 2016, 18, 118.	3.5	28
56	Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 630-639.	2.8	17
57	Anti-TNF $\pm$ treatment decreases the previously increased serum Indian Hedgehog levels in patients with ankylosing spondylitis and affects the expression of functional Hedgehog pathway target genes. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 646-651.	3.4	15
58	Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis. <i>Current Medicinal Chemistry</i> , 2015, 22, 1943-1955.	2.4	15
59	ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. <i>Joint Bone Spine</i> , 2014, 81, 98-100.	1.6	16
60	ACTH as a treatment for acute crystal-induced arthritis: Update on clinical evidence and mechanisms of action. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 648-653.	3.4	17
61	ACTH as first line treatment for acute gout in 181 hospitalized patients. <i>Joint Bone Spine</i> , 2013, 80, 291-294.	1.6	33
62	B cells tell scleroderma fibroblasts to produce collagen. <i>Arthritis Research and Therapy</i> , 2013, 15, 125.	3.5	23
63	Adrenocorticotrophic hormone: A powerful but underappreciated therapeutic tool for acute crystal induced arthritis?. <i>World Journal of Rheumatology</i> , 2013, 3, 6.	0.5	2
64	B cell depletion in scleroderma lung disease: A promising new treatment?. <i>World Journal of Rheumatology</i> , 2013, 3, 9.	0.5	0
65	B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. <i>Arthritis Research and Therapy</i> , 2012, 14, R145.	3.5	33
66	Treatment of Systemic Sclerosis-Associated Calcinosis: A Case Report of Rituximab-Induced Regression of CREST-Related Calcinosis and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 822-829.	3.4	68
67	Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S17-22.	0.8	115
68	The Emerging Role of Dickkopf-1 in Bone Biology: Is It the Main Switch Controlling Bone and Joint Remodeling?. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 170-177.	3.4	86
69	Microalbuminuria in rheumatoid arthritis in the post penicillamine/gold era: association with hypertension, but not therapy or inflammation. <i>Clinical Rheumatology</i> , 2011, 30, 477-484.	2.2	15
70	Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo. <i>Rheumatology International</i> , 2011, 31, 841-842.	3.0	3
71	Uric acid and cardiovascular risk in rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 1354-1355.	1.9	17
72	B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-7.	1.6	35

#	ARTICLE	IF	CITATIONS
73	Wnt Pathway and IL-17: Novel Regulators of Joint Remodeling in Rheumatic Diseases. Looking Beyond the RANK-RANKL-OPG Axis. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 369-383.	3.4	53
74	Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 127-136.	3.4	48
75	Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2010, 62, 150-158.	6.7	223
76	Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. <i>Rheumatology</i> , 2010, 49, 271-280.	1.9	348
77	Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R116.	3.5	24
78	Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	59
79	Vision loss in giant cell arteritis: case-based review. <i>Rheumatology International</i> , 0, , .	3.0	1